Literature DB >> 16944951

Alterations in the mitochondrial proteome of adriamycin resistant MCF-7 breast cancer cells.

Rachael Strong1, Takeo Nakanishi, Douglas Ross, Catherine Fenselau.   

Abstract

A 2D-gel based comparative proteomic analysis has been conducted of changes in mitochondrial protein abundances in MCF-7 human breast cancer cells selected for resistance to Adriamycin accompanied by verapamil. We identified and compared 156 unique proteins from 184 spots. Eleven mitochondrial proteins were found with abundances altered more than 2-fold. Transcription was evaluated for two of these, using quantitative RT-PCR. Implications of the changes are considered with respect to drug resistance.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16944951     DOI： 10.1021/pr060207c

Source DB:  PubMed          Journal:  J Proteome Res        ISSN： 1535-3893            Impact factor:   4.466


  11 in total

1.  Integration of 18O labeling and solution isoelectric focusing in a shotgun analysis of mitochondrial proteins.

Authors:  Jinshan Wang; Peter Gutierrez; Nathan Edwards; Catherine Fenselau
Journal:  J Proteome Res       Date:  2007-11-10       Impact factor: 4.466

2.  A Combined N-terminomics and Shotgun Proteomics Approach to Investigate the Responses of Human Cells to Rapamycin and Zinc at the Mitochondrial Level.

Authors:  Joanna Bons; Charlotte Macron; Catherine Aude-Garcia; Sebastian Alvaro Vaca-Jacome; Magali Rompais; Sarah Cianférani; Christine Carapito; Thierry Rabilloud
Journal:  Mol Cell Proteomics       Date:  2019-03-15       Impact factor: 5.911

3.  Quantitative proteomics analysis of mitochondrial proteins in lung adenocarcinomas and normal lung tissue using iTRAQ and tandem mass spectrometry.

Authors:  Wei Li; Xuede Zhang; Wei Wang; Ruiying Sun; Boxuan Liu; Yuefeng Ma; Wei Zhang; Li Ma; Yaofeng Jin; Shuanying Yang
Journal:  Am J Transl Res       Date:  2017-09-15       Impact factor: 4.060

Review 4.  Regulation of mitochondrial respiratory chain biogenesis by estrogens/estrogen receptors and physiological, pathological and pharmacological implications.

Authors:  Jin-Qiang Chen; Patrick R Cammarata; Christopher P Baines; James D Yager
Journal:  Biochim Biophys Acta       Date:  2009-06-23

5.  Discovery of IL-18 as a novel secreted protein contributing to doxorubicin resistance by comparative secretome analysis of MCF-7 and MCF-7/Dox.

Authors:  Ling Yao; Yan Zhang; Keying Chen; Xiaofang Hu; Lisa X Xu
Journal:  PLoS One       Date:  2011-09-08       Impact factor: 3.240

Review 6.  Comparative mitochondrial proteomics: perspective in human diseases.

Authors:  Yujie Jiang; Xin Wang
Journal:  J Hematol Oncol       Date:  2012-03-18       Impact factor: 17.388

Review 7.  Mass spectrometry-based proteomics in molecular diagnostics: discovery of cancer biomarkers using tissue culture.

Authors:  Debasish Paul; Avinash Kumar; Akshada Gajbhiye; Manas K Santra; Rapole Srikanth
Journal:  Biomed Res Int       Date:  2013-03-17       Impact factor: 3.411

8.  Cancer cell growth and survival as a system-level property sustained by enhanced glycolysis and mitochondrial metabolic remodeling.

Authors:  Lilia Alberghina; Daniela Gaglio; Cecilia Gelfi; Rosa M Moresco; Giancarlo Mauri; Paola Bertolazzi; Cristina Messa; Maria C Gilardi; Ferdinando Chiaradonna; Marco Vanoni
Journal:  Front Physiol       Date:  2012-09-12       Impact factor: 4.566

9.  Metabolomic approach to evaluating adriamycin pharmacodynamics and resistance in breast cancer cells.

Authors:  Bei Cao; Mengjie Li; Weibin Zha; Qijin Zhao; Rongrong Gu; Linsheng Liu; Jian Shi; Jun Zhou; Fang Zhou; Xiaolan Wu; Zimei Wu; Guangji Wang; Jiye Aa
Journal:  Metabolomics       Date:  2013-03-20       Impact factor: 4.290

10.  Quantitative proteomics analysis identifies mitochondria as therapeutic targets of multidrug-resistance in ovarian cancer.

Authors:  Xiulan Chen; Shasha Wei; Ying Ma; Jie Lu; Gang Niu; Yanhong Xue; Xiaoyuan Chen; Fuquan Yang
Journal:  Theranostics       Date:  2014-09-18       Impact factor: 11.556
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.